[1] Pesa J, Choudhry Z, Courcy JD, et al.Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries[J]. BMC Neurol, 2024, 24(1): 385. [2] Gilhus NE, Tzartos S, Evoli A, et al.Myasthenia gravis[J]. Nat Rev Dis Primers,2019, 5(1):30. [3] Estévez DAG, Fernández JP.Myasthenia gravis. Update on diagnosis and therapy[J]. Med Clin (Barc), 2023, 161(3): 119-127. [4] Claytor B, Cho S, Li Y.Myasthenic crisis[J]. Muscle Nerve, 2023, 68(1): 8-19. [5] Antonioni A, Raho EM, Carlucci D, et al.The Incidence of Myasthenia Gravis in the Province of Ferrara, Italy, in the Period of 2008-2022: An Update on a 40-Year Observation and the Influence of the COVID-19 Pandemic[J]. J Clin Med, 2023, 13(1): 236. [6] Hendricks TM, Bhatti MT, Hodge DO, et al.Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study[J]. Am J Ophthalmol, 2019, 205: 99-105. [7] Maddison P, Ambrose PA, Sadalage G, et al.A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England[J]. Neuroepidemiology, 2019, 53(1-2): 93-99. [8] Breiner A, Widdifield J, Katzberg HD, et al.Epidemiology of myasthenia gravis in Ontario, Canada[J]. Neuromuscul Disord, 2016, 26(1): 41-46. [9] Chen J, Tian D, Zhang C, et al.Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study[J]. Lancet Reg Health West Pac, 2020, 5: 100063. [10] Ramos-Fransi A, Rojas-García R, Segovia S, et al.Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry[J]. Eur J Neurol, 2015, 22(7): 1056-1061. [11] Neumann B, Angstwurm K, Mergenthaler P, et al.Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases[J]. Neurology, 2020, 94(3): e299-e313. [12] Gilhus NE.Myasthenia Gravis[J]. N Engl J Med, 2016, 375(26):2570-2581. [13] Kanikannan MA, Reddy PK, Mathukumalli NL, et al.Impact of Thymectomy on Crisis Incidence and Quality of Life amongst Generalised Myasthenia Gravis Patients[J]. Neurol India, 2022, 70(6): 2427-2431. [14] Morren J, Li Y.Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review[J]. Muscle Nerve, 2018, 58(3): 344-358. [15] 吴涛, 涂来慧, 张仁琴. 胸腺瘤术后重症肌无力六例报告[J]. 中华神经科杂志, 2001, 34(4): 256. [16] 杨根荣, 曹建西, 赵明理. 胸腺瘤手术后早期新发重症肌无力的误诊分析[J]. 中国实用神经疾病杂志, 2019, 22(14): 1593-1597. [17] Kim A, Choi S, Kang CH, et al.Risk factors for developing post-thymectomy myasthenia gravis in patients with thymoma[J]. Muscle Nerve, 2021, 63(4): 531-537. [18] 刘浩然, 方文涛, 谷志涛. 胸腺瘤手术后新发重症肌无力的研究进展[J]. 肿瘤防治研究, 2023, 50(10): 941-945. [19] Mandaliya R, Kulandaivel K, Nowotarski N, et al. A Challenging Diagnosis of Fluctuating Dyspnea: Myasthenia Gravis[J]. J Clin Diagn Res, 2015, 9(6): OD06-OD08. [20] Sun XG, Wang YL, Liu YH,et al.Myasthenia gravis appearing after thymectomy[J]. J Clin Neurosci, 2011, 18(1):57-60. [21] Yamada Y, Yoshida S, Iwata T, et al.Risk factors for developing postthymectomy myasthenia gravis in thymoma patients[J]. Ann Thorac Surg, 2015, 99(3): 1013-1019. [22] Ching J, Richards D, Lewis RA, et al.Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis[J]. Muscle Nerve, 2021, 64(4): 483-487. [23] Li Y, Wang H, Chen P, et al.Clinical outcome and predictive factors of postoperative myasthenic crisis in 173 thymomatous myasthenia gravis patients[J]. Int J Neurosci, 2018, 128(2): 103-109. [24] Liu C, Liu P, Zhang XJ, et al.Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies[J]. J Cardiothorac Surg, 2020, 15(1): 270. [25] Huang Y, Su L, Zhang Y, et al.Risk Factors for Postoperative Myasthenic Crisis After Thymectomy in Patients With Myasthenia Gravis[J]. J Surg Res, 2021, 262: 1-5. [26] Trikha I, Singh S, Goyal V, et al.Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial[J]. J Neurol, 2007, 254(8): 989-995. [27] Wang Y, Huan X, Jiao K, et al.Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study[J]. Clin Immunol, 2022, 241: 109058. [28] Barth D, Nouri MN, Ng E, et al.Comparison of IVIg and PLEX in patients with myasthenia gravis[J]. Neurology, 2011, 76(23): 2017-2023. [29] Gajdos P, Tranchant C, Clair B, et al.Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial[J]. Arch Neurol, 2005, 62(11): 1689-1693. [30] Rabinstein AA, Wijdicks EFM.Weaning from the ventilator using BiPAP in myasthenia gravis[J]. Muscle Nerve, 2003, 27(2): 252-253. [31] Hehir MK, Li Y.Diagnosis and Management of Myasthenia Gravis[J]. Continuum (MinneapMinn), 2022, 28(6):1615-1642. [32] Bae JS, Go SM, Kim BJ.Clinical predictors of steroid-induced exacerbation in myasthenia gravis[J]. J Clin Neurosci, 2006, 13(10): 1006-1010. [33] Yeo CJJ, Pleitez MY.Eculizumab in refractory myasthenic crisis[J]. Muscle Nerve, 2018, 58(2): E13-E15. [34] Strano CMM, Sorrenti B, Bosco L, et al.Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report[J]. J Neurol, 2022, 269(11): 6152-6154. [35] Vinciguerra C, Bevilacqua L, Toriello A, et al.Starting eculizumab as rescue therapy in refractory myasthenic crisis[J]. Neurol Sci, 2023, 44(10): 3707-3709. |